Answer
Belzutifan binds HIF-2α and, under hypoxia or impaired VHL protein function, blocks its interaction with hypoxia-inducible factor 1 beta (HIF-1b), reducing transcription and expression of HIF-2α target genes.
Sources for this answer
- WELIREG 40 mg film-coated tabletsMerck Sharp & Dohme (UK) Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 12Document updated
Sources checked